Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model
JCO Clinical Cancer Informatics · 2024
DOI: 10.1200/cci.24.00108 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Hikaru Nakahara und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Sustained Virologic Response. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Postsustained virologic response (SVR) screening following clinical guidelines does not address individual risk of hepatocellular carcinoma (HCC). Our aim is to provide tailored screening for patients using machine learning to predict HCC incidence after SVR. METHODS Using clinical data from 1,028 SVR patients, we developed an HCC prediction model using a random survival forest (RSF). Model performance was assessed using Harrel's c-index and validated in an independent cohort of 737 SVR patients. Shapley additive explanation (SHAP) facilitated feature quantification, whereas optimal cutoffs were determined using maximally selected rank statistics. We used Kaplan-Meier analysis to compare cumulative HCC incidence between risk groups. RESULTS We achieved c-index scores and 95% CIs of 0.90 (0.85 to 0.94) and 0.80 (0.74 to 0.85) in the derivation and validation cohorts, respectively, in a model using platelet count, gamma-glutamyl transpeptidase, sex, age, and ALT. Stratification resulted in four risk groups: low, intermediate, high, and very high. The 5-year cumulative HCC incidence rates and 95% CIs for these groups were as follows: derivation: 0% (0 to 0), 3.8% (0.6 to 6.8), 26.2% (17.2 to 34.3), and 54.2% (20.2 to 73.7), respectively, and validation: 0.7% (0 to 1.6), 7.1% (2.7 to 11.3), 5.2% (0 to 10.8), and 28.6% (0 to 55.3), respectively. CONCLUSION The integration of RSF and SHAP enabled accurate HCC risk classification after SVR, which may facilitate individualized HCC screening strategies and more cost-effective care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Clinical and Molecular Genetics, Hiroshima University, Hiroshima, Japan.
- Department of Clinical Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Hikaru Nakahara, Atsushi Ono, C Nelson Hayes, Serami Murakami, Kenji Yamaoka, Hauri Bao, Shinsuke Uchikawa, Hatsue Fujino, Masataka Tsuge, Shiro Oka
Zitieren
APA
Nakahara, H., Ono, A., Hayes, C. N., Shirane, Y., Miura, R., Fujii, Y., Murakami, S., Yamaoka, K., Bao, H., Uchikawa, S., Fujino, H., Murakami, E., Kawaoka, T., Miki, D., Tsuge, M., Oka, S., Hiroshima Liver Study Group, & TransSCOT Consortium (2024). Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00108
Vancouver
Nakahara H, Ono A, Hayes CN, Shirane Y, Miura R, Fujii Y, et al. Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.24.00108
BibTeX
@article{Nakahara2024,
author = {Nakahara, Hikaru and Ono, Atsushi and Hayes, C Nelson and Shirane, Yuki and Miura, Ryoichi and Fujii, Yasutoshi and Murakami, Serami and Yamaoka, Kenji and Bao, Hauri and Uchikawa, Shinsuke and Fujino, Hatsue and Murakami, Eisuke and Kawaoka, Tomokazu and Miki, Daiki and Tsuge, Masataka and Oka, Shiro and Hiroshima Liver Study Group, Hiroshima Liver Study Group and TransSCOT Consortium, TransSCOT Consortium},
title = {Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model},
journal = {JCO Clinical Cancer Informatics},
year = {2024},
doi = {10.1200/cci.24.00108}
}
EUVIMED